Sipuleucel-T

N/A

Report date: 2026/05/25 20:02:40

Base Information

Drug NameSipuleucel-T
Drug Alias Name普罗文奇Provenge普列威APC-8015APC-8015F
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy > Monocyte cell therapy +[5] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsBone metastasesHormone-Resistant Prostate NeoplasmsNeoplasm Metastasis +[5] 
Global Approved IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2010/04/19
Country/TerritoryCanadaUnited StatesNetherlands +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesDendreon Uk Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Danrui Biomedical Technology Co LtdDendreon Corp
Inactive CompaniesUniversity of Texas Southwestern Medical CenterDuke UniversityDendreon Uk Ltd +[7] 
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsBone metastasesHormone-Resistant Prostate NeoplasmsNeoplasm Metastasis

Other Information

ATC CodeL03AX17
Related LinksWikipediaDrugBankKEGG